Next Quarterly Earnings
Pre-market — typically early morning before trading starts (around 7–8 a.m. CET).
Samsung Biologics, a global leading CDMO headquartered in South Korea, provides comprehensive services for the development and GMP-compliant manufacturing of biopharmaceutical drugs. The company supports pharmaceutical companies worldwide in the efficient production of high-quality biologics.
Pre-market — typically early morning before trading starts (around 7–8 a.m. CET).
Samsung Biologics is scheduled to report its next quarterly earnings on 10/27/2026. Pre-market — typically early morning before trading starts (around 7–8 a.m. CET).
Samsung Biologics last reported quarterly earnings on 7/23/2026 (Q2 2026). Earnings per share (EPS) came in at 9,307.43 KRW.
Across its last 5 earnings reports, Samsung Biologics stock moved by ±3.5% on average the following day. The largest reaction was +10.1% on 07/23/2026; 3 of 5 reactions were positive.
Samsung Biologics has beaten analyst EPS estimates in 1 of its last 5 evaluated quarters (beat rate: 20%).
Use the 'Subscribe in calendar' button on this page to add all dates to Google Calendar, Apple Calendar or Outlook. Dates update automatically when they change.
Basis: price reactions to the last 5 report dates (close to close).
Basis: 5 quarters with an analyst estimate and reported EPS.
Past price reactions are not a reliable indicator of future performance.